| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NAGENiagen Bioscience Inc | 503.58M | 6.31 | 57.36 | 19.18% | 16.38% | 28.91% | 2.37% | 0.06 |
| BTXBlackRock Technology and Private Equity Term Trust | 808.8M | 6.93 | 40.76 | -81.13% | 87.75% | 1.87% | 34.27% | |
| HALOHalozyme Therapeutics, Inc. | 8.45B | 71.82 | 20.94 | 22.44% | 47.91% | 118.17% | 5.55% | 4.14 |
| RPRXRoyalty Pharma plc | 16.97B | 39.72 | 20.80 | -3.86% | 32.55% | 7.95% | 16.32% | 0.74 |
| REGNRegeneron Pharmaceuticals, Inc. | 76.63B | 741.92 | 19.35 | 8.27% | 32.13% | 14.79% | 4.78% | 0.09 |
| GMABGenmab A/S | 20.85B | 33.85 | 2.79 | 30.67% | 46.8% | 114.25% | 36.37% | 0.03 |
| DNAGinkgo Bioworks Holdings, Inc. | 464.86M | 9.58 | -0.91 | -9.71% | -188% | -60.66% | 0.65 | |
| PRMEPrime Medicine, Inc. | 720.24M | 3.99 | -2.42 | -33.02% | -121.95% | 0.27 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 18.32M | 23.27M | 34.75M | 59.08M | 34.16M | 26.39M |
| Revenue Growth % | - | 0.27% | 0.49% | 0.7% | -0.42% | -0.23% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | 18.32M | 23.27M | 34.75M | 59.08M | 34.16M | 26.39M |
| Gross Margin % | 1% | 1% | 1% | 1% | 1% | 1% |
| Gross Profit Growth % | - | 0.27% | 0.49% | 0.7% | -0.42% | -0.23% |
| Operating Expenses | 31.34M | 48.89M | 70.36M | 85.72M | 103.58M | 100.89M |
| OpEx % of Revenue | 1.71% | 2.1% | 2.02% | 1.45% | 3.03% | 3.82% |
| Selling, General & Admin | 8.65M | 10.22M | 16.95M | 24.9M | 33.31M | 30.74M |
| SG&A % of Revenue | 0.47% | 0.44% | 0.49% | 0.42% | 0.98% | 1.16% |
| Research & Development | 13.21M | 24.8M | 39.23M | 48.36M | 56.52M | 55.11M |
| R&D % of Revenue | 0.72% | 1.07% | 1.13% | 0.82% | 1.65% | 2.09% |
| Other Operating Expenses | 9.49M | 13.87M | 14.18M | 12.46M | 13.74M | 15.04M |
| Operating Income | -13.03M | -25.62M | -35.61M | -26.65M | -69.42M | -74.5M |
| Operating Margin % | -0.71% | -1.1% | -1.02% | -0.45% | -2.03% | -2.82% |
| Operating Income Growth % | - | -0.97% | -0.39% | 0.25% | -1.61% | -0.07% |
| EBITDA | -2.43M | -13M | -19.36M | -8.4M | -49.92M | -50.92M |
| EBITDA Margin % | -0.13% | -0.56% | -0.56% | -0.14% | -1.46% | -1.93% |
| EBITDA Growth % | - | -4.34% | -0.49% | 0.57% | -4.94% | -0.02% |
| D&A (Non-Cash Add-back) | 10.59M | 12.63M | 16.25M | 18.25M | 19.5M | 23.58M |
| EBIT | -13.85M | -23.55M | -34.34M | -26.65M | -69.42M | -74.5M |
| Net Interest Income | 0 | -5K | -7K | 587K | 5.05M | 3.11M |
| Interest Income | 0 | 0 | 0 | 587K | 5.05M | 3.11M |
| Interest Expense | 0 | 5K | 7K | 0 | 0 | 0 |
| Other Income/Expense | 0 | 1.9M | 1.26M | 587K | 5.06M | 3.09M |
| Pretax Income | -13.03M | -23.73M | -34.35M | -26.06M | -64.36M | -71.41M |
| Pretax Margin % | -0.71% | -1.02% | -0.99% | -0.44% | -1.88% | -2.71% |
| Income Tax | 562K | -6.17M | -7.31M | -3.73M | -13.74M | -9.38M |
| Effective Tax Rate % | 1.04% | 0.74% | 0.79% | 0.86% | 0.79% | 0.87% |
| Net Income | -13.59M | -17.56M | -27.04M | -22.33M | -50.62M | -62.03M |
| Net Margin % | -0.74% | -0.75% | -0.78% | -0.38% | -1.48% | -2.35% |
| Net Income Growth % | - | -0.29% | -0.54% | 0.17% | -1.27% | -0.23% |
| Net Income (Continuing) | -13.59M | -17.56M | -27.04M | -22.33M | -50.62M | -62.03M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.12 | -0.15 | -0.24 | -0.26 | -0.51 | -0.61 |
| EPS Growth % | - | -0.25% | -0.6% | -0.08% | -0.96% | -0.2% |
| EPS (Basic) | -0.12 | -0.15 | -0.24 | -0.26 | -0.51 | -0.61 |
| Diluted Shares Outstanding | 114.82M | 114.82M | 114.82M | 85.32M | 99.68M | 102.36M |
| Basic Shares Outstanding | 114.82M | 114.82M | 114.82M | 85.32M | 99.68M | 102.36M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 7.79M | 16.65M | 22.54M | 124.95M | 94.9M | 68.14M |
| Cash & Short-Term Investments | 0 | 0 | 0 | 88.27M | 86.98M | 59.43M |
| Cash Only | 0 | 0 | 0 | 33.39M | 16.36M | 27.6M |
| Short-Term Investments | 0 | 0 | 0 | 54.88M | 70.63M | 31.84M |
| Accounts Receivable | 7.77M | 15.88M | 21.14M | 30.29M | 3.84M | 5.27M |
| Days Sales Outstanding | 154.9 | 249.03 | 222.02 | 187.14 | 41.07 | 72.91 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 21K | 774K | 1.41M | 6.39M | 4.07M | 3.43M |
| Total Non-Current Assets | 254.53M | 278.73M | 281.92M | 296.26M | 280.32M | 257.42M |
| Property, Plant & Equipment | 4.32M | 5.98M | 20.13M | 41.46M | 38.13M | 33.28M |
| Fixed Asset Turnover | 4.24x | 3.89x | 1.73x | 1.42x | 0.90x | 0.79x |
| Goodwill | 77.11M | 83.98M | 83.98M | 83.98M | 83.98M | 83.98M |
| Intangible Assets | 172.98M | 186.64M | 176.32M | 167.24M | 155.47M | 138.06M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 115K | 2.13M | 1.5M | 3.58M | 2.75M | 2.1M |
| Total Assets | 262.32M | 295.38M | 304.46M | 421.21M | 375.23M | 325.56M |
| Asset Turnover | 0.07x | 0.08x | 0.11x | 0.14x | 0.09x | 0.08x |
| Asset Growth % | - | 0.13% | 0.03% | 0.38% | -0.11% | -0.13% |
| Total Current Liabilities | 6.14M | 14.28M | 20.58M | 26.02M | 23.12M | 15.09M |
| Accounts Payable | 806K | 469K | 2.92M | 2.97M | 4.41M | 2.3M |
| Days Payables Outstanding | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 4.55M | 3.79M | 4.92M | 8.18M | 7.8M | 6.67M |
| Current Ratio | 1.27x | 1.17x | 1.10x | 4.80x | 4.11x | 4.52x |
| Quick Ratio | 1.27x | 1.17x | 1.10x | 4.80x | 4.11x | 4.52x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 38M | 45.57M | 49.58M | 53.82M | 37.52M | 22.85M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 2.27M | 2.01M | 13.27M | 24.02M | 22.07M | 19.38M |
| Deferred Tax Liabilities | 0 | 28.93M | 21.96M | 21.34M | 11.35M | 2.31M |
| Other Non-Current Liabilities | 35.72M | 6.4M | 5.12M | 4.13M | 3.23M | 1.04M |
| Total Liabilities | 44.13M | 59.84M | 70.16M | 79.84M | 60.64M | 37.94M |
| Total Debt | 2.58M | 2.59M | 13.85M | 25.8M | 25.56M | 23.16M |
| Net Debt | 2.58M | 2.59M | 13.85M | -7.59M | 9.2M | -4.43M |
| Debt / Equity | 0.01x | 0.01x | 0.06x | 0.08x | 0.08x | 0.08x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | - | -5124.60x | -5087.00x | - | - | - |
| Total Equity | 218.19M | 235.54M | 234.31M | 341.37M | 314.58M | 287.62M |
| Equity Growth % | - | 0.08% | -0.01% | 0.46% | -0.08% | -0.09% |
| Book Value per Share | 1.90 | 2.05 | 2.04 | 4.00 | 3.16 | 2.81 |
| Total Shareholders' Equity | 218.19M | 235.54M | 234.31M | 341.37M | 314.58M | 287.62M |
| Common Stock | 218.19M | 0 | 0 | 12K | 12K | 12K |
| Retained Earnings | 0 | 0 | 0 | 11.25M | -39.37M | -101.4M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 9K | 50K | 27K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -5.2M | 3.62M | -5.67M | -3.59M | 2.35M | -39.66M |
| Operating CF Margin % | -0.28% | 0.16% | -0.16% | -0.06% | 0.07% | -1.5% |
| Operating CF Growth % | - | 1.7% | -2.57% | 0.37% | 1.65% | -17.9% |
| Net Income | -13.59M | -17.56M | -27.04M | -22.33M | -50.62M | -62.03M |
| Depreciation & Amortization | 10.92M | 13.14M | 16.25M | 18.25M | 19.5M | 23.58M |
| Stock-Based Compensation | 6.66M | 9.16M | 15.06M | 18.32M | 24.82M | 21.5M |
| Deferred Taxes | 557K | -6.18M | -7.33M | -6.42M | -12.54M | -9.04M |
| Other Non-Cash Items | -818K | 331K | 9K | -572K | -3.68M | -3.5M |
| Working Capital Changes | -8.92M | 4.73M | -2.63M | -10.83M | 24.87M | -10.17M |
| Change in Receivables | -4.29M | 339K | 6.02M | -12.74M | 26.9M | -625K |
| Change in Inventory | 0 | 0 | -1.51M | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 1.51M | 15.07M | 920K | -2.41M |
| Cash from Investing | -12.1M | -26.98M | -4.03M | -73.31M | -18.38M | 37.88M |
| Capital Expenditures | -255K | -1.75M | -4.07M | -17.17M | -1.64M | -1.88M |
| CapEx % of Revenue | 0.01% | 0.08% | 0.12% | 0.29% | 0.05% | 0.07% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 1.9M | -1.22M | -1.44M | -4.44M | -400K |
| Cash from Financing | 17.29M | 23.36M | 9.7M | 110.74M | -892K | 13.02M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 17.29M | 23.36M | 9.7M | 14.5M | -892K | 1.65M |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -5.45M | 1.87M | -9.74M | -20.75M | 703K | -41.54M |
| FCF Margin % | -0.3% | 0.08% | -0.28% | -0.35% | 0.02% | -1.57% |
| FCF Growth % | - | 1.34% | -6.22% | -1.13% | 1.03% | -60.09% |
| FCF per Share | -0.05 | 0.02 | -0.08 | -0.24 | 0.01 | -0.41 |
| FCF Conversion (FCF/Net Income) | 0.38x | -0.21x | 0.21x | 0.16x | -0.05x | 0.64x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 2.61M | 16K |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -6.23% | -7.74% | -11.51% | -7.76% | -15.43% | -20.6% |
| Return on Invested Capital (ROIC) | -4.43% | -8.38% | -10.98% | -6.87% | -15.84% | -18.41% |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% |
| Net Margin | -74.18% | -75.46% | -77.82% | -37.8% | -148.16% | -235.05% |
| Debt / Equity | 0.01x | 0.01x | 0.06x | 0.08x | 0.08x | 0.08x |
| Interest Coverage | - | -5124.60x | -5087.00x | - | - | - |
| FCF Conversion | 0.38x | -0.21x | 0.21x | 0.16x | -0.05x | 0.64x |
| Revenue Growth | - | 27.02% | 49.34% | 70.02% | -42.17% | -22.75% |
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Service | 18.78M | 12.18M | 11.95M |
| Service Growth | - | -35.16% | -1.90% |
| Royalty | 1.37M | 1.28M | 576K |
| Royalty Growth | - | -6.00% | -55.18% |
| Milestone | 33.87M | - | - |
| Milestone Growth | - | - | - |
| License | 5.05M | - | - |
| License Growth | - | - | - |
OmniAb, Inc. (OABI) reported $21.1M in revenue for fiscal year 2024. This represents a 15% increase from $18.3M in 2019.
OmniAb, Inc. (OABI) saw revenue decline by 22.8% over the past year.
OmniAb, Inc. (OABI) reported a net loss of $63.7M for fiscal year 2024.
OmniAb, Inc. (OABI) has a return on equity (ROE) of -20.6%. Negative ROE indicates the company is unprofitable.
OmniAb, Inc. (OABI) had negative free cash flow of $35.3M in fiscal year 2024, likely due to heavy capital investments.